Supernus (SUPN) Reports Receipt of Paragraph IV for Generic Trokendi XR (ACT)
Tweet Send to a Friend
Supernus Pharmaceuticals (Nasdaq: SUPN) announced that on August 20, 2014, the Company received a Paragraph IV Notice Letter ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
